Pelican Therapeutics
LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • ImPACT
    • ComPACT
    • Pelican’s PTX-35 Co-stimulatory Antibody
    • Scientific Publications
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • PTX-35
    • Expanded Access
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact
  • Pelican Therapeutics

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics Inc. Reports Second Quarter 2017 Results

Aug 14, 2017

Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics

Jul 3, 2017

Heat Biologics Appoints Damien Hallet as Vice President of CMC Development

Jul 3, 2017

Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award

Jun 28, 2017

Heat Biologics to Present at the 2017 BIO International Convention

Jun 12, 2017

Heat Biologics to Present at the 2017 Marcum Microcap Conference

Jun 7, 2017

Heat Biologics Presents Poster on its Phase 2 Trial Evaluating HS-410 at ASCO Annual Meeting

Jun 5, 2017

Heat Biologics to Present Poster at 2017 ASCO Annual Meeting

May 30, 2017

Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017

May 11, 2017

Heat Biologics Announces Completion of Acquisition of Pelican Therapeutics

May 1, 2017
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...21
    © 2019 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn